Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy

By Dong-Ho Kim, M. Behlke, S. Rose, Mi-Sook Chang, Sangdun Choi, John J. Rossi. Nature Biotechnology, 2005

909 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/fd5450cf0df79a45c00a70467da456045f3ce715

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Molecular Biology

Citations in the corpus

Interfering with disease: a progress report on siRNA-based therapeutics (2007, background): “One study suggests that slightly longer siRNAs, which need to be processed by Dicer before they can be incorporated into RISC, can be used as Dicer substrates and maintain silencing activity, although these longer siRNAs are more complicated to synthesize and could have an increased propensity to ac”
Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone (2008, background): “As synthetic RNA duplexes 25–30 nucleotides in length are up to 100-fold more potent than corresponding conventional 21-mer siRN”
IDT SciTools: a suite for analysis and design of nucleic acid oligomers (2008, methodology): “The RNAi design software tool allows users to predict effective short synthetic 27-mer siRNA duplexes that are delivered to target cells (6).”
RNA-based Therapeutics- Current Progress and Future Prospects (2012, methodology): “All steps of siRNA and shRNA are the same after processing by Dicer/TRBP. 62 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved RISC, the dsRNA may be designed asymmetrically with a 2 nt 30 overhang at one end and a blunt end at the other (Kim et al., 2005).”
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. (2005, methodology): “Knockdown of FKHR protein using siRNAs siRNA analyses were performed using 27 bp RNA duplexes (Kim et al., 2005).”
siRNA vs. shRNA: similarities and differences. (2009, background): “Increasing the length of the siRNA duplex to 29–30 nt with a 2 nt 3′ overhang only at one end of the duplex (specifically antisense [113]) appears to improve efficacy [114].”
Strategies for silencing human disease using RNA interference (2007, background): “3a ), and for some siRNA–target combinations the use of these longer dsRNAs can increase the potency of PTG”
Illuminating the silence: understanding the structure and function of small RNAs (2007, background): “Recent studies have shown that pre-Dicer-cleavage dsRNA triggers are more potent in silencing genes than are siRNAs (Ref”
Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. (2005, background): “These hairpin-shaped pre-miRNAs are transported to the cytoplasm, where they are subsequently cleaved by Dicer to generate an w 22 nt miRNA (Hutvagner et al., 2001, Ketting et al., 2001, Kim 2005).”
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras (2006, background): “5a , bottom panels), as 21- to 23-nt long siRNAs have been shown to bypass the Dicer ste”
RNAi therapeutics: principles, prospects and challenges. (2007, background): “If the siRNA effector is delivered to the cell it will “activate” RISC, resulting in potent and specific silencing of the targeted mRNA.”
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA (2011, neutral): “An additional mechanism for the inhibition of translation by mRNA containing dsRNA contaminants could involve RNA interference. dsRNA greater than 27 bp in length is a substrate for Dicer (27), whose action can lead to a speciﬁc suppression of translation through the RNAi pathway (28). dsRNA contami”
Current prospects for RNA interference-based therapies (2011, background): “In some cases, the silencing potency of Dicer-ready siRNAs can be greater than for siRNAs 29, 30 .”